MENLO PARK, Calif., March 28, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The common stock and warrants are being offered under the company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). BioPharmX intends to use the net proceeds of the offering for general corporate purposes, which may include funding research and development, increasing working capital, and acquisitions or investments in businesses, products, or technologies that are complementary to its own.
Maxim Group LLC is acting as lead book-running manager and CRT Capital Group LLC is acting as co-book-running manager for the offering. Rodman & Renshaw, a unit of H.C Wainwright & Co., LLC, is acting as co-manager for the offering.
The common stock and warrants are being offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective registration statement, a copy of which may be obtained, when available, at the website of the SEC at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement and accompanying prospectus also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter, and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
Certain statements contained herein, including the company's intention to complete the offering and the expected use of net proceeds, are not based on historical fact and are "forward-looking statements" within the meaning of the applicable securities laws and regulations. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size of terms of the offering. These forward-looking statements, actual events or results could differ materially from those stated here. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended October 31, 2015, filed with the SEC on December 15, 2015, the preliminary prospectus supplement related to the proposed public offering and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect the company's results of operations, which would, in turn, have a significant and adverse impact on the company's stock price. The company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
BioPharmX is a registered trademark of BioPharmX, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biopharmx-corporation-announces-proposed-public-offering-of-common-stock-and-warrants-300241611.html
SOURCE BioPharmX Corporation